Immune Thrombocytopenia historical perspective

	Immune Thrombocytopenia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Immune Thrombocytopenia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Immune Thrombocytopenia historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Immune Thrombocytopenia historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Immune Thrombocytopenia historical perspective
CDC on Immune Thrombocytopenia historical perspective
Immune Thrombocytopenia historical perspective in the news
Blogs on Immune Thrombocytopenia historical perspective
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Immune Thrombocytopenia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]

Overview

Idiopathic Thrombocytopenia (ITP) was first described by a German poet Paul Werlhof, in 1735. He referred to classical signs of ITP as mucosal bleeding, black and purple spots on the patient's arm, due to this description, ITP is called Werlhof's disease.
In 1881, an Italian pathologist, Guilio Bizzozero was the first to discover the role of platelet in hemostasis.
In 1889, George Hayem proved the association between purpura and the development of thrombocytopenia by physically counting the patient's platelet.
In 1916, a medical student Paul Kasnelson developed the idea of excessive destruction of platelets by spleen. Soon he persuaded his professor Schloffer to splectomize a patient with ITP, thereafter they found outstanding increase of platelet count following splenectomy.
In 1951, Harrington experiment in Missouri proved the hypothesis that a humoral factor causes platelet destruction. He exchanged whole blood of himself and a patient with chronic purpura who had the same blood group. after the exchange, the patient platelet count remained unchanged but his platelet count which was normal prior to exchange dropped to 10 x 10⁹ /L .
in 1951, an American hematologist, Maxwell Wintrobe, showed immunosuppressive therapy with corticosteroids.
In 1981, Paul Imbach in Switzerland, realized the role of Fc receptors on splenic macrophages led to first successful use of intravascular immunoglobulin.